BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned / S. Viviani, P.L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis, V. Bonfante, U. Vitolo, A. Pulsoni, A.M. Liberati, G. Specchia, P. Valagussa, A. Rossi, F. Zaja, E.M. Pogliani, P. Pregno, M. Gotti, A. Gallamini, D. Rota Scalabrini, G. Bonadonna, A. Gianni. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 365:3(2011 Jul 21), pp. 203-212. [10.1056/NEJMoa1100340]

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

A. Rambaldi;A. Gianni
2011

Abstract

BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Young Adult ; Prednisone ; Disease-Free Survival ; Dacarbazine ; Humans ; Salvage Therapy ; Vinblastine ; Cyclophosphamide ; Adult ; Hematopoietic Stem Cell Transplantation ; Antineoplastic Combined Chemotherapy Protocols ; Adolescent ; Hodgkin Disease ; Etoposide ; Male ; Neoplasm Staging ; Combined Modality Therapy; Vincristine ; Bleomycin ; Doxorubicin ; Kaplan-Meier Estimate ; Middle Aged ; Procarbazine ; Female ; Proportional Hazards Models ; Remission Induction
Settore MED/06 - Oncologia Medica
21-lug-2011
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/160222
Citazioni
  • ???jsp.display-item.citation.pmc??? 85
  • Scopus 352
  • ???jsp.display-item.citation.isi??? 311
social impact